Status:
ACTIVE_NOT_RECRUITING
Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
Dysautonomia International
Conditions:
Postural Tachycardia Syndrome
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The mechanisms underlying POTS are not well understood. Though heterogeneous in nature, patients often present with symptoms that include fatigue, orthostatic lightheadedness and tachycardia, "brain f...
Eligibility Criteria
Inclusion
- Age: 18-70 years old
- POTS, as defined by the presence of any of the following criteria:
- For patients age 20 or older, increase in heart rate ≥ 30 bpm within ten minutes of upright posture (tilt test or standing) from a supine position (For patients age 18-19, heart rate increase must be \>40 bpm)
- Associated with related symptoms that are worse with upright posture and that improve with recumbency
- Chronic symptoms that have lasted for longer than six months
- In the absence of other disorders, medications, or functional states that are known to predispose to orthostatic tachycardia
- Baseline eating period \> 12-hour window
Exclusion
- Taking insulin within the last 6 months.
- Manifest diabetes, defined as HbA1c \> 7.0% given a 0.3% margin of error in lab readings, or diagnosis of diabetes.
- Known inflammatory and/or rheumatologic disease.
- Active tobacco abuse or illicit drug use or history of treatment for alcohol abuse.
- Pregnant or breast-feeding women.
- Shift workers with variable (e.g. nocturnal) hours.
- Caregivers for dependents requiring frequent nocturnal care/sleep interruptions.
- Planned travel to a time zone with greater than a 3-hour difference during study period.
- History of a major adverse cardiovascular event within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)).
- Uncontrolled arrhythmia (i.e. rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria).
- History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e. hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion).
- History of adrenal disease.
- History of malignancy undergoing active treatment, except non-melanoma skin cancer.
- Known history of type I diabetes.
- History of eating disorder.
- History of cirrhosis.
- History of stage 4 or 5 chronic kidney disease or requiring dialysis.
- History of HIV/AIDS.
- Currently enrolled in a weight-loss or weight-management program.
- On a special or prescribed diet for other reasons (e.g. Celiac disease).
- Currently taking any medication that is meant for, or has known effect on, appetite.
- Any history of surgical intervention for weight management.
- Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness).
- A score of \>16 on the Epworth Sleepiness Scale (ESS).
- Depression determined by the Beck Depression Inventory (BDI-II) (unless previously diagnosed and well-controlled)
- Failure to use the smartphone app for documentation (defined as \<2 meals/day for ≥3 days during baseline).
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05409651
Start Date
July 1 2022
End Date
June 1 2025
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Altman Clinical and Translational Research Institute
La Jolla, California, United States, 92093